MFGE8

(redirected from lactadherin)

MFGE8

A gene on chromosome 15q25 that encodes medin (milk fat globule-EGF factor 8 protein), which plays a key role in maintaining epithelial homeostasis and in promoting mucosal healing. Medin promotes VEGF-dependent neovascularisation, helps remove apoptotosed cells, binds to phosphatidylserine-enriched cell surfaces in a receptor-independent manner and binds rotavirus, inhibiting its replication.
References in periodicals archive ?
Lactadherin binds to elastin--a starting point for medin amyloid formation?
BULLETIN BOARD: ACCP) presented new data this week on its proprietary humanized monoclonal antibody, Angiolix, which confirmed that Angiolix(R) binds with high affinity to the its target, lactadherin, resulting in anti-angiogenesis and significant tumor growth inhibition in MCF-7 and MX-1 breast cancer xenografts.
Agamemnon Epenetos, Access Pharmaceuticals' Chief Scientific Officer, Europe explained, "Competitive binding experiments with a variety of ligands shows that Angiolix binds lactadherin selectively.
Lactadherin is not expressed in normal tissues and therefore it is a suitable marker for tumor targeting.
This new data shows that Angiolix interferes with binding of lactadherin on new blood vessels and many different tumor types including breast, ovary, stomach, as well with surrounding tissues the extra cellular matrix around tumors and new blood vessels formed by tumors.
The rotavirus mistakenly identifies lactadherin as this home-grown carbohydrate and latches onto it in order to anchor itself in the gut.
OTCBB:SMPM), a cancer stem cell company focused on in-licensing differentiated oncology compounds and anti-cancer agents, will present preclinical data on Angiolix, a humanized monoclonal antibody, that recognizes a migrating adhesion molecule called Lactadherin, at the academic community sponsored Stem Cells and Cancer conference March 2-7 in Keystone, Colorado.
BULLETIN BOARD: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves.
Lactadherin is a potent stimulator of angiogenesis, promoting the growth of new blood vessels to support tumor growth.
Data suggests that tumor cells express Lactadherin which is a factor in the proliferation of the vasculature which is necessary to support tumor growth.
Somanta's recent data suggests that tumor cells express Lactadherin which is a factor in the growth of tumor vasculature.